摘要
目的探讨核苷酸切除修复酶基因118密码子(ERCC 1118)和751密码子(XPD 751)多态性与晚期胃癌患者对5-氟尿嘧啶(5-Fu)/铂类药物化疗敏感性的关系。方法 91例患者给予5-Fu/铂类药物方案治疗,化疗前检测ERCC1 118和XPD 751基因型。观察化疗疗效与ERCC1 118和XPD 751多态性的关系。结果 本组患者化疗有效率为37.4%。ERCC1 118的3种基因型化疗有效率比较差异无统计学意义(P>0.05);XPD 751的杂合子Lys/Gln基因型的化疗有效率为11.1%,低于纯合子Lys/Lys和Gln/Gln基因型的38.0%和100.0%,差异有统计意义(P<0.01)。结论核苷酸切除修复酶基因XPD 751基因多态性与晚期胃癌对5-Fu/铂类药物化疗疗效有关。
Objective To explore the relationship between polymorphisms of ERCC1 118 and XPD 751 and the response to fluoropymidine（5-Fu）/platin-based chemotherapy in advanced gastric cancer.Methods 91 cases were treated with 5-Fu/platin-based chemotherapy,and the genotypes of ERCC1 118 and XPD 751 were detected before the therapy.The relationship between the chemotherapy effect and genetic polymorphisms of ERCC1 118 and XPD 751 were observed.Results The chemotherapy efficiency rate of this group was 37.4%.The efficiency rates were of no significant difference among different genotypes of ERCC1 118（P0.05）.The chemotherapy efficiency rate of XPD 751 Lys/Gln genotype was 11.1%,which was respectively lower than 38.0% and 100.0% of the Lys/Lys and Gln/Gln genotype,and the differences were statistically significant（P0.01）.Conclusion Nucleotide excision repair enzyme XPD 751 polymorphism has something to do with the sensitivity to 5-Fu/platin based chemotherapy in advanced gastric cancer.
出处
《临床合理用药杂志》
2011年第2期3-5,共3页
Chinese Journal of Clinical Rational Drug Use
基金
江苏省科技厅社会发展重点项目(No:BS2007010)
